A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-05/ECHO-306-05)
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-715-05
- Sponsors Incyte Corporation
- 25 Jul 2024 Results assessing addition of epacadostat, a potent and highly selective IDO1 inhibitor, to pembrolizumab and chemotherapy for metastatic NSCLC presented in the BMC Cancer
- 09 Dec 2020 Status changed from active, no longer recruiting to completed.
- 05 Jul 2020 This trial has been completed in Hungary according to European Clinical Trials Database record.